1. Scrip
  2. >>Business
  3. >>Earnings

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

Expecting Little Impact From Recent Alnylam Option

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

BridgeBio's Attruby sped through Q1 sales expectations in ATTR-CM (Shutterstock)
Key Takeaways
  • BridgeBio’s first full quarter of Attruby sales in ATTR-CM far exceeded expectations in Q1 at $36.7m, prompting analysts to consider raising full-year forecasts from about $150m to more than $200m.
  • The company said new diagnoses, Attruby’s clinical trial results, and pricing and access for the drug drove the outsized performance.
  • Pfizer acknowledged the impact of the Attruby launch during its Q1 call when talking about its blockbuster Vyndaquel/Vyndamax franchise, BridgeBio’s biggest competitor in ATTR-CM.

BridgeBio Pharma’s Attruby (acoramidis) delivered $36.7m in sales during the first quarter of 2025 – three times analyst consensus of $12m for the transthyretin amyloidosis with cardiomyopathy (ATTR-CM) drug’s first...

Palo Alto, CA-based BridgeBio reported its Q1 earnings after the stock market closed on 29 April and saw its share price close up 4.3% on 30 April at $38 based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

More from Scrip

In partnership with

Podcast Series: Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.